Back HCV Treatment Approved HCV Drugs

Approved HCV Drugs

EASL 2012: GS-7977 with Interferon/Ribavirin Cures Most Treatment-Naive Hepatitis C Patients in 12 Weeks

Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

Read more:

AASLD 2011: Sustained Response is Durable among Hepatitis C Patients Treated with Telaprevir

Almost all chronic hepatitis C patients who achieved sustained virological response (SVR) using the recently approved HCV protease inhibitor telaprevir (Incivek) plus pegylated interferon and ribavirin continued to have undetectable viral load nearly 2 years later, according to data presented at the recent American Association for the Study of Liver Disease (AASLD) Liver Meeting in San Francisco.alt

Read more:

FDA Approves Pegasys Autoinjector for Hepatitis C Patients

The U.S. Food and Drug Administration (FDA) recently approved an autoinjector for pegyalted interferon alfa-2a, which will make it more convenient for hepatitis C patients to self-administer the medication.alt

Read more:

PegIntron Label Updated to Include Use with New Direct-Acting HCV Agents

The U.S. Food and Drug Administration (FDA) last week announced revisions to the product label for pegylated interferon alfa-2b (brand name PegIntron) to incorporate information about its use with the recently approved hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek), as well as use by people with psychiatric conditions.alt

Read more:

Telaprevir plus Standard Therapy Can Produce Hepatitis C Cure in Less Time

Adding the hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) to pegylated interferon plus ribavirin increases the chances of sustained response and many patients achieved a cure with a shorter course of therapy, researchers reported in the September 15, 2011, New England Journal of Medicine.alt

Read more: